Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China
单位:[1]Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Peoples R China[2]Southern Med Univ, Dept Infect Dis, Nanfang Hosp, Guangzhou, Peoples R China[3]Guangzhou Eighth Peoples Hosp, Guangzhou, Peoples R China[4]Fudan Univ, Shanghai, Peoples R China[5]Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China[6]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[7]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[8]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[9]Jilin Univ, Hosp 1, Jilin, Jilin, Peoples R China[10]Assembly Biosci, Foster City, CA USA[11]Gilead Sci, Foster City, CA USA[12]Assembly Biosci, South San Fransisco, CA USA[13]Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
第一作者单位:[1]Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Peoples R China[2]Southern Med Univ, Dept Infect Dis, Nanfang Hosp, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Liang Xieer,Hou Jinlin,Guan Yujuan,et al.Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China[J].JOURNAL OF HEPATOLOGY.2023,78:S1153-S1154.doi:10.1016/S0168-8278(23)03289-0.
APA:
Liang, Xieer,Hou, Jinlin,Guan, Yujuan,Zhang, Zhanqing,Xie, Qing...&Niu, Junqi.(2023).Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China.JOURNAL OF HEPATOLOGY,78,
MLA:
Liang, Xieer,et al."Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China".JOURNAL OF HEPATOLOGY 78.(2023):S1153-S1154